IN VIVO ANTICANCER EVALUATION OF (2-AMINO-3,4,5-TRIMETHOXYPHENYL) (6-METHOXY-1H-INDOL-3-YL) METHANONE
DOI:
https://doi.org/10.22159/ijpps.2017v9i11.20439Keywords:
Combretastatin A-4, in-vivo, Human Tumor Xenograft model, Aroylindole derivativeAbstract
Objective: The design and development of Combretastatin A-4 analogues as anticancer agent has always attracted the attention of scientific community involved in anticancer research. The aim of the present work was to investigate the in-vivo cytotoxic activity of a novel CA-4 analogues i.e., (2-amino-3,4,5-trimethoxyphenyl)(6-methoxy-1H-indol-3-yl)methanone.
Method: The in-vivo cytotoxic activity of test compound was examined using Human Tumor Xenograft model on MCF-7 cancer cell line in Balb/c mice.
Result: The test compound exhibited excellent cytotoxic activity against MCF-7 (0.013 µM), and colon HT-29 (0.143 µM), slightly higher than CA-4 activity. Relative Tumor Volume (RTV) value was found to increase rapidly in control group A during the period of 1 to 18 days indicating the higher growth rates of tumor. On the other hand group B and C showed slower growth rate of tumor as a result of treatment with CA-4 and test compound, respectively. The group B treated with CA-4 (5 mg/kg) showed significant inhibition in tumor growth during day 5 to 18 with %TGI in range of 47.24%-62.31% as compared to control group. The group C treated with test compound  (5mg/kg) caused significant inhibition in tumor growth during day 5 to 18 with %TGI in range of 55.66%-75.93% as compared to control group. The % survival value was found 100% indicating that CA-4 and test compound were nontoxic at the dose of 5mg/kg under experimental conditions.
Conclusion: The parameters of In-vivo anticancer evaluation i.e., relative tumour volume and % tumor growth inhibition showed better anticancer potential of test compound. It was further supported by non-toxic nature of test compound as indicated by 100% survival value determined at the dose of 5 mg/kg during in-vivo studies.Downloads
References
Lawrence B, John L, Keith P, Goodman and Gilman‟s. The Pharmacological Basis of Therapeutics. 11th ed. Mc. Graw-Hill Medical Publishing Division, New York, USA; 2006.
DeVita VT, Lawrence TS, Steven AR. Cancer-principles and practice of oncology. 8th ed. Wolters Kluwer/lippincott Williams and Wilkins, Philadelphia, USA; 2008.
World Cancer Report. WHO; 2014.
Mohammadian M, Mahdavifar N, Salehiniya H. Trend of incidence of gastric cancer in sistan and baluchestan province, iran. Asian J Pharm Clin Res, 2016;9:230-23.
Santhosh MP, Harshini AK. Knowledge and awareness about oral cancer among undergraduate dental students. Asian J Pharm Clin Res 2016;9:165-7.
el-Zayat AA, Degen D, Drabek S, Clark GM, Pettit GR, Von Hoff DD. In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from combretum caffrum (arid shrub). Anticancer Drugs 1993;4:19-25.
Rajak H, Dewangan PK, Patel V, Jain DK, Singh A, Veerasamy R, et al. Design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomers. Curr Pharm Des 2013;19:1923-55.
Tron GC, Pirali T, Sorba G, Pagliai F, Busacca S, Genazzani AA. Medicinal chemistry of combretastatin A4: present and future directions. J Med Chem 2006;49:3033-44.
Patel VK, Rajak H. Significance of amino group substitution at combretastatin a-4 and phenstatin analogs. Lett Drug Des Discovery 2016;13:943-51.
Patel VK, Singh Chouhan K, Singh A, Kumar Jain D, Veerasamy R, Singh Pawar R, et al. Development of structure activity correlation model on azetidin-2-ones as tubulin polymerization inhibitors. Lett Drug Des Discovery 2015;12:351-65.
Lu Y, Chen J, Xiao M, Li W, Miller DD. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res 2012;29:2943-71.
Attard G, Greystoke A, Kaye S, Bono JD. Update on tubulin-binding agents. Pathol Biol 2005;54:72-84.
Prinz H. Recent advances in the field of tubulin polymerization inhibitors. Expert Rev Anticancer Ther 2000;2:695-708.
Kingston DGI. Tubulin-interactive natural products as anticancer agents. J Nat Prod 2009;72:507-15.
Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002;2:1-17.
Liou JP, Chang YL, Kuo FM, Chang CW, Tseng HY, Wang CC, et al. Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents. J Med Chem 2004;47:4247-57.
Liou JP, Mahindroo N, Chang CW, Guo FM, Lee SW, Tan UK, et al. Structure-activity relationship studies of 3-aroylindoles as potent antimitotic agents. Chem Med Chem 2006;1:1106-18.
Wu YS, Coumar MS, Chang JY, Sun HY, Kuo FM, Kuo CC, Chen YJ, et al. Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach. J Med Chem 2009;52:4941-5.
La Regina G, Sarkar T, Bai R, Edler MC, Saletti R, Coluccia A, et al. New arylthioindoles and related bioisosteres at the sulfur bridging group. 4. Synthesis, tubulin polymerization, cell growth inhibition, and molecular modeling studies. J Med Chem 2009;52:7512-27.
La Regina G, Bai R, Rensen WM, Di Cesare E, Coluccia A, Piscitelli F, et al. Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors. J Med Chem 2013;56:123-49.
Zhao DG, Chen J, Du YR, Ma YY, Chen YX, Gao K, et al. Synthesis and structure-activity relationships of N-methyl-5,6,7-trimethoxylindoles as novel antimitotic and vascular disrupting agents. J Med Chem 2013;56:1467-77.
Patel VK, Rajak H. Synthesis, biological evaluation and molecular docking studies of 2-amino-3, 4, 5-trimethoxy-aroylindole derivatives as novel anticancer agents. Bioorg Med Chem Lett 2016;26:2115-8.
Published
How to Cite
Issue
Section
